Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment - United States, January-June 2020.
Identifieur interne : 000C99 ( Main/Corpus ); précédent : 000C98; suivant : 000D00Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment - United States, January-June 2020.
Auteurs : Lara Bull-Otterson ; Elizabeth B. Gray ; Daniel S. Budnitz ; Heather M. Strosnider ; Lyna Z. Schieber ; Joseph Courtney ; Macarena C. García ; John T. Brooks ; William R. Mac Kenzie ; Adi V. GundlapalliSource :
- MMWR. Morbidity and mortality weekly report [ 1545-861X ] ; 2020.
English descriptors
- KwdEn :
- COVID-19 (drug therapy), Chloroquine (therapeutic use), Coronavirus Infections (drug therapy), Female (MeSH), Humans (MeSH), Hydroxychloroquine (therapeutic use), Male (MeSH), Practice Patterns, Physicians' (statistics & numerical data), Specialization (statistics & numerical data), Treatment Outcome (MeSH), United States (MeSH).
- MESH :
- chemical , therapeutic use : Chloroquine, Hydroxychloroquine.
- geographic : United States.
- drug therapy : COVID-19, Coronavirus Infections.
- statistics & numerical data : Practice Patterns, Physicians', Specialization.
- Female, Humans, Male, Treatment Outcome.
Abstract
Hydroxychloroquine and chloroquine, primarily used to treat autoimmune diseases and to prevent and treat malaria, received national attention in early March 2020, as potential treatment and prophylaxis for coronavirus disease 2019 (COVID-19) (1). On March 20, the Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for chloroquine phosphate and hydroxychloroquine sulfate in the Strategic National Stockpile to be used by licensed health care providers to treat patients hospitalized with COVID-19 when the providers determine the potential benefit outweighs the potential risk to the patient.* Following reports of cardiac and other adverse events in patients receiving hydroxychloroquine for COVID-19 (2), on April 24, 2020, FDA issued a caution against its use† and on June 15, rescinded its EUA for hydroxychloroquine from the Strategic National Stockpile.§ Following the FDA's issuance of caution and EUA rescindment, on May 12 and June 16, the federal COVID-19 Treatment Guidelines Panel issued recommendations against the use of hydroxychloroquine or chloroquine to treat COVID-19; the panel also noted that at that time no medication could be recommended for COVID-19 pre- or postexposure prophylaxis outside the setting of a clinical trial (3). However, public discussion concerning the effectiveness of these drugs on outcomes of COVID-19 (4,5), and clinical trials of hydroxychloroquine for prophylaxis of COVID-19 continue.¶ In response to recent reports of notable increases in prescriptions for hydroxychloroquine or chloroquine (6), CDC analyzed outpatient retail pharmacy transaction data to identify potential differences in prescriptions dispensed by provider type during January-June 2020 compared with the same period in 2019. Before 2020, primary care providers and specialists who routinely prescribed hydroxychloroquine, such as rheumatologists and dermatologists, accounted for approximately 97% of new prescriptions. New prescriptions by specialists who did not typically prescribe these medications (defined as specialties accounting for ≤2% of new prescriptions before 2020) increased from 1,143 prescriptions in February 2020 to 75,569 in March 2020, an 80-fold increase from March 2019. Although dispensing trends are returning to prepandemic levels, continued adherence to current clinical guidelines for the indicated use of these medications will ensure their availability and benefit to patients for whom their use is indicated (3,4), because current data on treatment and pre- or postexposure prophylaxis for COVID-19 indicate that the potential benefits of these drugs do not appear to outweigh their risks.
DOI: 10.15585/mmwr.mm6935a4
PubMed: 32881845
PubMed Central: PMC7470458
Links to Exploration step
pubmed:32881845Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment - United States, January-June 2020.</title>
<author><name sortKey="Bull Otterson, Lara" sort="Bull Otterson, Lara" uniqKey="Bull Otterson L" first="Lara" last="Bull-Otterson">Lara Bull-Otterson</name>
</author>
<author><name sortKey="Gray, Elizabeth B" sort="Gray, Elizabeth B" uniqKey="Gray E" first="Elizabeth B" last="Gray">Elizabeth B. Gray</name>
</author>
<author><name sortKey="Budnitz, Daniel S" sort="Budnitz, Daniel S" uniqKey="Budnitz D" first="Daniel S" last="Budnitz">Daniel S. Budnitz</name>
</author>
<author><name sortKey="Strosnider, Heather M" sort="Strosnider, Heather M" uniqKey="Strosnider H" first="Heather M" last="Strosnider">Heather M. Strosnider</name>
</author>
<author><name sortKey="Schieber, Lyna Z" sort="Schieber, Lyna Z" uniqKey="Schieber L" first="Lyna Z" last="Schieber">Lyna Z. Schieber</name>
</author>
<author><name sortKey="Courtney, Joseph" sort="Courtney, Joseph" uniqKey="Courtney J" first="Joseph" last="Courtney">Joseph Courtney</name>
</author>
<author><name sortKey="Garcia, Macarena C" sort="Garcia, Macarena C" uniqKey="Garcia M" first="Macarena C" last="García">Macarena C. García</name>
</author>
<author><name sortKey="Brooks, John T" sort="Brooks, John T" uniqKey="Brooks J" first="John T" last="Brooks">John T. Brooks</name>
</author>
<author><name sortKey="Mac Kenzie, William R" sort="Mac Kenzie, William R" uniqKey="Mac Kenzie W" first="William R" last="Mac Kenzie">William R. Mac Kenzie</name>
</author>
<author><name sortKey="Gundlapalli, Adi V" sort="Gundlapalli, Adi V" uniqKey="Gundlapalli A" first="Adi V" last="Gundlapalli">Adi V. Gundlapalli</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32881845</idno>
<idno type="pmid">32881845</idno>
<idno type="doi">10.15585/mmwr.mm6935a4</idno>
<idno type="pmc">PMC7470458</idno>
<idno type="wicri:Area/Main/Corpus">000C99</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000C99</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment - United States, January-June 2020.</title>
<author><name sortKey="Bull Otterson, Lara" sort="Bull Otterson, Lara" uniqKey="Bull Otterson L" first="Lara" last="Bull-Otterson">Lara Bull-Otterson</name>
</author>
<author><name sortKey="Gray, Elizabeth B" sort="Gray, Elizabeth B" uniqKey="Gray E" first="Elizabeth B" last="Gray">Elizabeth B. Gray</name>
</author>
<author><name sortKey="Budnitz, Daniel S" sort="Budnitz, Daniel S" uniqKey="Budnitz D" first="Daniel S" last="Budnitz">Daniel S. Budnitz</name>
</author>
<author><name sortKey="Strosnider, Heather M" sort="Strosnider, Heather M" uniqKey="Strosnider H" first="Heather M" last="Strosnider">Heather M. Strosnider</name>
</author>
<author><name sortKey="Schieber, Lyna Z" sort="Schieber, Lyna Z" uniqKey="Schieber L" first="Lyna Z" last="Schieber">Lyna Z. Schieber</name>
</author>
<author><name sortKey="Courtney, Joseph" sort="Courtney, Joseph" uniqKey="Courtney J" first="Joseph" last="Courtney">Joseph Courtney</name>
</author>
<author><name sortKey="Garcia, Macarena C" sort="Garcia, Macarena C" uniqKey="Garcia M" first="Macarena C" last="García">Macarena C. García</name>
</author>
<author><name sortKey="Brooks, John T" sort="Brooks, John T" uniqKey="Brooks J" first="John T" last="Brooks">John T. Brooks</name>
</author>
<author><name sortKey="Mac Kenzie, William R" sort="Mac Kenzie, William R" uniqKey="Mac Kenzie W" first="William R" last="Mac Kenzie">William R. Mac Kenzie</name>
</author>
<author><name sortKey="Gundlapalli, Adi V" sort="Gundlapalli, Adi V" uniqKey="Gundlapalli A" first="Adi V" last="Gundlapalli">Adi V. Gundlapalli</name>
</author>
</analytic>
<series><title level="j">MMWR. Morbidity and mortality weekly report</title>
<idno type="eISSN">1545-861X</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>COVID-19 (drug therapy)</term>
<term>Chloroquine (therapeutic use)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Female (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Male (MeSH)</term>
<term>Practice Patterns, Physicians' (statistics & numerical data)</term>
<term>Specialization (statistics & numerical data)</term>
<term>Treatment Outcome (MeSH)</term>
<term>United States (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>United States</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term>
<term>Coronavirus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Practice Patterns, Physicians'</term>
<term>Specialization</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Hydroxychloroquine and chloroquine, primarily used to treat autoimmune diseases and to prevent and treat malaria, received national attention in early March 2020, as potential treatment and prophylaxis for coronavirus disease 2019 (COVID-19) (1). On March 20, the Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for chloroquine phosphate and hydroxychloroquine sulfate in the Strategic National Stockpile to be used by licensed health care providers to treat patients hospitalized with COVID-19 when the providers determine the potential benefit outweighs the potential risk to the patient.* Following reports of cardiac and other adverse events in patients receiving hydroxychloroquine for COVID-19 (2), on April 24, 2020, FDA issued a caution against its use<sup>†</sup>
and on June 15, rescinded its EUA for hydroxychloroquine from the Strategic National Stockpile.<sup>§</sup>
Following the FDA's issuance of caution and EUA rescindment, on May 12 and June 16, the federal COVID-19 Treatment Guidelines Panel issued recommendations against the use of hydroxychloroquine or chloroquine to treat COVID-19; the panel also noted that at that time no medication could be recommended for COVID-19 pre- or postexposure prophylaxis outside the setting of a clinical trial (3). However, public discussion concerning the effectiveness of these drugs on outcomes of COVID-19 (4,5), and clinical trials of hydroxychloroquine for prophylaxis of COVID-19 continue.<sup>¶</sup>
In response to recent reports of notable increases in prescriptions for hydroxychloroquine or chloroquine (6), CDC analyzed outpatient retail pharmacy transaction data to identify potential differences in prescriptions dispensed by provider type during January-June 2020 compared with the same period in 2019. Before 2020, primary care providers and specialists who routinely prescribed hydroxychloroquine, such as rheumatologists and dermatologists, accounted for approximately 97% of new prescriptions. New prescriptions by specialists who did not typically prescribe these medications (defined as specialties accounting for ≤2% of new prescriptions before 2020) increased from 1,143 prescriptions in February 2020 to 75,569 in March 2020, an 80-fold increase from March 2019. Although dispensing trends are returning to prepandemic levels, continued adherence to current clinical guidelines for the indicated use of these medications will ensure their availability and benefit to patients for whom their use is indicated (3,4), because current data on treatment and pre- or postexposure prophylaxis for COVID-19 indicate that the potential benefits of these drugs do not appear to outweigh their risks.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32881845</PMID>
<DateCompleted><Year>2020</Year>
<Month>09</Month>
<Day>04</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>12</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1545-861X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>69</Volume>
<Issue>35</Issue>
<PubDate><Year>2020</Year>
<Month>Sep</Month>
<Day>04</Day>
</PubDate>
</JournalIssue>
<Title>MMWR. Morbidity and mortality weekly report</Title>
<ISOAbbreviation>MMWR Morb Mortal Wkly Rep</ISOAbbreviation>
</Journal>
<ArticleTitle>Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment - United States, January-June 2020.</ArticleTitle>
<Pagination><MedlinePgn>1210-1215</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.15585/mmwr.mm6935a4</ELocationID>
<Abstract><AbstractText>Hydroxychloroquine and chloroquine, primarily used to treat autoimmune diseases and to prevent and treat malaria, received national attention in early March 2020, as potential treatment and prophylaxis for coronavirus disease 2019 (COVID-19) (1). On March 20, the Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for chloroquine phosphate and hydroxychloroquine sulfate in the Strategic National Stockpile to be used by licensed health care providers to treat patients hospitalized with COVID-19 when the providers determine the potential benefit outweighs the potential risk to the patient.* Following reports of cardiac and other adverse events in patients receiving hydroxychloroquine for COVID-19 (2), on April 24, 2020, FDA issued a caution against its use<sup>†</sup>
and on June 15, rescinded its EUA for hydroxychloroquine from the Strategic National Stockpile.<sup>§</sup>
Following the FDA's issuance of caution and EUA rescindment, on May 12 and June 16, the federal COVID-19 Treatment Guidelines Panel issued recommendations against the use of hydroxychloroquine or chloroquine to treat COVID-19; the panel also noted that at that time no medication could be recommended for COVID-19 pre- or postexposure prophylaxis outside the setting of a clinical trial (3). However, public discussion concerning the effectiveness of these drugs on outcomes of COVID-19 (4,5), and clinical trials of hydroxychloroquine for prophylaxis of COVID-19 continue.<sup>¶</sup>
In response to recent reports of notable increases in prescriptions for hydroxychloroquine or chloroquine (6), CDC analyzed outpatient retail pharmacy transaction data to identify potential differences in prescriptions dispensed by provider type during January-June 2020 compared with the same period in 2019. Before 2020, primary care providers and specialists who routinely prescribed hydroxychloroquine, such as rheumatologists and dermatologists, accounted for approximately 97% of new prescriptions. New prescriptions by specialists who did not typically prescribe these medications (defined as specialties accounting for ≤2% of new prescriptions before 2020) increased from 1,143 prescriptions in February 2020 to 75,569 in March 2020, an 80-fold increase from March 2019. Although dispensing trends are returning to prepandemic levels, continued adherence to current clinical guidelines for the indicated use of these medications will ensure their availability and benefit to patients for whom their use is indicated (3,4), because current data on treatment and pre- or postexposure prophylaxis for COVID-19 indicate that the potential benefits of these drugs do not appear to outweigh their risks.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bull-Otterson</LastName>
<ForeName>Lara</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Gray</LastName>
<ForeName>Elizabeth B</ForeName>
<Initials>EB</Initials>
</Author>
<Author ValidYN="Y"><LastName>Budnitz</LastName>
<ForeName>Daniel S</ForeName>
<Initials>DS</Initials>
</Author>
<Author ValidYN="Y"><LastName>Strosnider</LastName>
<ForeName>Heather M</ForeName>
<Initials>HM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Schieber</LastName>
<ForeName>Lyna Z</ForeName>
<Initials>LZ</Initials>
</Author>
<Author ValidYN="Y"><LastName>Courtney</LastName>
<ForeName>Joseph</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>García</LastName>
<ForeName>Macarena C</ForeName>
<Initials>MC</Initials>
</Author>
<Author ValidYN="Y"><LastName>Brooks</LastName>
<ForeName>John T</ForeName>
<Initials>JT</Initials>
</Author>
<Author ValidYN="Y"><LastName>Mac Kenzie</LastName>
<ForeName>William R</ForeName>
<Initials>WR</Initials>
</Author>
<Author ValidYN="Y"><LastName>Gundlapalli</LastName>
<ForeName>Adi V</ForeName>
<Initials>AV</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>09</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>MMWR Morb Mortal Wkly Rep</MedlineTA>
<NlmUniqueID>7802429</NlmUniqueID>
<ISSNLinking>0149-2195</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>886U3H6UFF</RegistryNumber>
<NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010818" MajorTopicYN="N">Practice Patterns, Physicians'</DescriptorName>
<QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013038" MajorTopicYN="N">Specialization</DescriptorName>
<QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<CoiStatement>All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>9</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>9</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>9</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32881845</ArticleId>
<ArticleId IdType="doi">10.15585/mmwr.mm6935a4</ArticleId>
<ArticleId IdType="pmc">PMC7470458</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Int J Infect Dis. 2020 Aug;97:396-403</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32623082</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Jun 23;323(24):2493-2502</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32392282</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Interv Card Electrophysiol. 2020 May 16;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32418181</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Intern Med. 2020 Jul 6;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32628242</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Jul 23;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32706953</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Immunol Immunopathol. 1997 Sep;84(3):223-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9281381</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lupus. 1996 Jun;5 Suppl 1:S11-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8803904</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C99 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000C99 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidChloroV1 |flux= Main |étape= Corpus |type= RBID |clé= pubmed:32881845 |texte= Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment - United States, January-June 2020. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32881845" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a CovidChloroV1
![]() | This area was generated with Dilib version V0.6.38. | ![]() |